Opportunity Information: Apply for PA 07 073
Apply for PA 07 073
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Molecular genetics of drug addiction and related co morbidities (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Nov 20, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Independent school districts Special district governments Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities State governments Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Molecular genetics of drug addiction and related co morbidities (R01) opportunity (Funding Opportunity Number PA-07-073) is a National Institutes of Health discretionary grant program led by the National Institute on Drug Abuse (NIDA) with involvement from the National Institute of Mental Health (NIMH). It calls for standard NIH Research Project Grant (R01) applications that focus on uncovering the genetic and chromosomal factors that influence drug addiction risk, severity, and recovery. The core aim is to support molecular genetic studies that identify chromosomal loci, specific genetic variants, and haplotypes linked to either increased vulnerability or relative protection from developing substance dependence, as well as genetic factors that shape how individuals respond to addiction treatment.
The scientific scope is broad in terms of substances and outcomes. The announcement highlights addiction to stimulants such as cocaine, amphetamine, and caffeine; narcotics such as opiates; nicotine; sedative-hypnotics including benzodiazepines and barbiturates; cannabis; hallucinogens; and patterns of polysubstance abuse. Projects may be conducted in human populations or in animal models, as long as the work is directed toward identifying genetic contributors to addiction-related traits. In addition to genetic influences on addiction itself, the FOA specifically emphasizes interest in co-occurring psychiatric conditions that frequently intersect with substance use disorders, including major depression, schizophrenia, and bipolar disorder. In practice, this means proposed studies can examine shared genetic vulnerability across addiction and mental illness, genetic factors that distinguish subgroups of patients with different co morbidity profiles, or genetic variation that helps explain why some individuals develop psychiatric symptoms alongside substance dependence while others do not.
A major secondary emphasis is pharmacogenetics and treatment response. The NIH is signaling interest not only in who is more likely to become dependent, but also in who is more likely to benefit from particular interventions. This includes genetic and haplotype differences associated with variable responses to treatments for substance use disorders and to treatments aimed at associated co morbid mental health disorders. In other words, the announcement supports work that could advance more personalized approaches to prevention and care, by linking genetic differences to clinically meaningful outcomes like abstinence, relapse risk, medication response, side effect burden, or broader functional recovery.
This FOA uses the R01 mechanism, meaning it supports full research projects of the type typically used for hypothesis-driven or discovery-driven biomedical research. The number of awards and the amount of funding are not guaranteed; awards depend on available appropriations and the quality and merit of the applications received. The opportunity lists multiple receipt dates (rather than a single deadline), directing applicants to the full announcement for the specific schedule and submission details.
Eligibility is intentionally wide, reflecting the NIH goal of attracting strong applications across many research settings. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (including small businesses, though the mechanism is R01 rather than SBIR/STTR), local and state government entities, tribal governments and tribal organizations, public housing authorities, independent school districts, and special district governments. The program also states that foreign institutions are eligible to apply, that eligible federal agencies may apply, and that faith-based and community-based organizations may apply, as long as they meet NIH requirements.
Administratively, the opportunity falls under NIH and is categorized within health and education-related funding activities, with CFDA numbers 93.279 (Drug Abuse and Addiction Research Programs) and 93.242 (Mental Health Research Grants). The announcement was originally posted on November 20, 2006, and later archived on February 2, 2010, indicating it was an active program during that period and that applicants should consult the archived full text for historical requirements and context. The full announcement is linked at http://grants.nih.gov/grants/guide/pa-files/PA-07-073.html, and NIH provides an Office of Extramural Research (OER) webmaster contact for access or linking issues.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Molecular genetics of drug addiction and related co morbidities (R01).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-07-073.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant opportunity.
Which NIH Institutes are involved?
The program is led by the National Institute on Drug Abuse (NIDA) with involvement from the National Institute of Mental Health (NIMH).
What grant mechanism does this opportunity use?
This opportunity uses the standard NIH Research Project Grant (R01) mechanism.
What is the main purpose of this FOA?
The core aim is to support molecular genetic studies that uncover genetic and chromosomal factors influencing drug addiction, including risk, severity, recovery, and treatment response.
What types of genetic findings are emphasized?
The FOA highlights research that identifies chromosomal loci, specific genetic variants, and haplotypes associated with increased vulnerability or relative protection from developing substance dependence, as well as genetic factors tied to how people respond to treatment.
Does the FOA support research on addiction severity and recovery, not just risk?
Yes. The described focus includes genetic factors influencing risk, severity, and recovery from addiction.
Does this FOA include pharmacogenetics or treatment response research?
Yes. A major secondary emphasis is pharmacogenetics and treatment response, including genetic and haplotype differences linked to variable responses to treatments for substance use disorders and to treatments for related co morbid mental health disorders.
What kinds of treatment outcomes are mentioned as relevant?
The FOA describes clinically meaningful outcomes such as abstinence, relapse risk, medication response, side effect burden, and broader functional recovery.
What substances or categories of drugs are within scope?
The scientific scope is broad and includes addiction related to:
- Stimulants (for example, cocaine, amphetamine, caffeine)
- Narcotics (for example, opiates)
- Nicotine
- Sedative-hypnotics (for example, benzodiazepines, barbiturates)
- Cannabis
- Hallucinogens
- Polysubstance abuse patterns
Can projects focus on polysubstance use rather than a single drug?
Yes. The announcement explicitly mentions interest in patterns of polysubstance abuse.
Are human studies required, or are animal models allowed?
Projects may be conducted in human populations or in animal models, as long as the work is directed toward identifying genetic contributors to addiction-related traits.
Does the FOA support research on co-occurring mental health conditions?
Yes. The FOA specifically emphasizes co-occurring psychiatric conditions that frequently intersect with substance use disorders.
Which psychiatric co morbidities are specifically mentioned?
The FOA highlights interest in major depression, schizophrenia, and bipolar disorder.
What types of co morbidity questions fit the FOA?
Examples described include studies that examine:
- Shared genetic vulnerability across addiction and mental illness
- Genetic factors that distinguish subgroups with different co morbidity profiles
- Genetic variation that helps explain why some individuals develop psychiatric symptoms alongside substance dependence while others do not
Is this a guaranteed funding opportunity?
No. The number of awards and the amount of funding are not guaranteed. Awards depend on available appropriations and the quality and merit of the applications received.
Is there a single application deadline?
No. The opportunity lists multiple receipt dates rather than a single deadline, and directs applicants to the full announcement for the specific schedule and submission details.
Who is eligible to apply?
Eligibility is described as broad. Eligible applicants include:
- Public and private institutions of higher education
- Nonprofit organizations (including those with and without 501(c)(3) status)
- For-profit organizations (including small businesses, though the mechanism is R01 rather than SBIR/STTR)
- Local and state government entities
- Tribal governments and tribal organizations
- Public housing authorities
- Independent school districts
- Special district governments
Are foreign institutions eligible to apply?
Yes. The program states that foreign institutions are eligible to apply.
Can federal agencies apply?
Yes. The program states that eligible federal agencies may apply.
Are faith-based or community-based organizations allowed to apply?
Yes. The opportunity states that faith-based and community-based organizations may apply, as long as they meet NIH requirements.
What funding activity categories does this opportunity fall under?
The opportunity is categorized within health and education-related funding activities.
What CFDA numbers are associated with this FOA?
The CFDA numbers listed are 93.279 (Drug Abuse and Addiction Research Programs) and 93.242 (Mental Health Research Grants).
When was this FOA posted, and what is its current status?
The announcement was originally posted on November 20, 2006 and later archived on February 2, 2010. This indicates it was active during that period; applicants are directed to consult the archived full text for historical requirements and context.
Where can the full announcement be found?
The full announcement is linked at: http://grants.nih.gov/grants/guide/pa-files/PA-07-073.html
Who should be contacted for access or linking issues to the announcement?
NIH provides an Office of Extramural Research (OER) webmaster contact for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Proteomics Diabetes, Obesity, And Endocrine, Digestive, Kidney, Urologic, And Hematologic Diseases (R01)
Previous opportunity: Research Grants for Studies of Hepatitis C in the Setting of Renal Disease (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 073
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 073) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 07 021 Funding Number: PA 07 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic Research in the Bladder and Lower Urinary Tract (R01) Apply for PA 07 023 Funding Number: PA 07 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanisms of Alcohol Associated Cancers (R01) Apply for PA 07 069 Funding Number: PA 07 069 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Chronic Insomnia Disorder (R01) Apply for PA 07 047 Funding Number: PA 07 047 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 07 048 Funding Number: PAR 07 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research On The Reduction And Prevention Of Suicidality (R01) Apply for PA 07 079 Funding Number: PA 07 079 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Risk Factors For Psychopathology Using Existing Data Sets (R01) Apply for PA 07 082 Funding Number: PA 07 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R01) Apply for PAR 07 086 Funding Number: PAR 07 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection Of The Central Nervous System (R01) Apply for PA 07 089 Funding Number: PA 07 089 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS, Severe Mental Illness And Homelessness (R01) Apply for PA 07 090 Funding Number: PA 07 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01) Apply for PA 07 100 Funding Number: PA 07 100 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Rural Mental Health and Drug Abuse Disorders (R01) Apply for PA 07 103 Funding Number: PA 07 103 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 07 111 Funding Number: PA 07 111 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R01) Apply for PA 07 113 Funding Number: PA 07 113 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R01) Apply for PA 07 132 Funding Number: PA 07 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development Of Frontal Cortex And Limbic System And Their Roles In Drug Abuse Or Mental Health (R01) Apply for PA 07 121 Funding Number: PA 07 121 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Sarcoidosis Research into the Cause of Multi organ Disease and Clinical Strategies for Therapy (R01) Apply for PA 07 136 Funding Number: PA 07 136 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Translational Research in Integrative Behavioral Science (R01) Apply for PAR 07 155 Funding Number: PAR 07 155 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Genetics And Genomics Of Drug Addiction (R03) Apply for PA 07 168 Funding Number: PA 07 168 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Functional Genetics and Genomics of Drug Addiction (R21) Apply for PA 07 167 Funding Number: PA 07 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 073", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.